Compare BVS & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BVS | PACB |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 617.1M | 419.8M |
| IPO Year | 2016 | 2010 |
| Metric | BVS | PACB |
|---|---|---|
| Price | $10.30 | $1.60 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $14.00 | $1.67 |
| AVG Volume (30 Days) | 440.5K | ★ 5.5M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 163.46 | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $568,087,000.00 | $93,468,000.00 |
| Revenue This Year | $7.52 | $11.32 |
| Revenue Next Year | $7.06 | $12.13 |
| P/E Ratio | $32.03 | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $5.81 | $0.85 |
| 52 Week High | $10.58 | $2.73 |
| Indicator | BVS | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 69.21 | 59.76 |
| Support Level | $8.43 | $1.52 |
| Resistance Level | N/A | $1.64 |
| Average True Range (ATR) | 0.38 | 0.10 |
| MACD | 0.13 | 0.04 |
| Stochastic Oscillator | 83.96 | 86.90 |
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.